Table 1. Summary of clinical trials examining DNA hypomethylating agents (DHA) alone or in combination with Histone Deacetylase inhibitors in hematological malignancies.

DHA	Phase	Combination	Hematological disease	Identifier	State
Azacitidine	I	Entinostat	AMLa, CMML, MDS,	NCT00101179b	Ongoing
			MDS, AML, CMML	NCT00528983	Ongoing
		VPA, ATRA	AML, MDS	NCT01575691	Completed
			AML, MDS	NCT00350818	Completed
		Belinostat	AHM	NCT00351975	Completed
			MDS	NCT01152346	Completed
			AML, CMML, MDS	NCT01519011	Completed
		Pracinostat	AHM, MDS	NCT00741234	Completed
			MDS	NCT01571648	Completed
		Panobinostat	AML, MDS, CMML	NCT01613976	Completed
		Sodium phenylbutyrate	AML, MDS	NCT00004871	Completed
			AML, MDS, CMML, HL, MM, NHL	NCT01908387	Terminated
	I/II	Mocetinostat	MDS	NCT02018926	Recruiting
		Romidepsin	HL, NHL	NCT01998035	Recruiting
		Vorinostat	AML, DMS	NCT00392353	Ongoing
			MDS	NCT01305460	Ongoing
			AML, MDS	NCT01835587	Ongoing
		Vorinostat, Gemtuzumab ogamicin	AML	NCT00895934	Completed
		Mocetinostat	AML, MDS	NCT00324220	Completed
	II		MDS, JMML	NCT02447666	Recruiting
			MDS	NCT01652781	Recruiting
			AML, MDS	NCT02204020	Recruiting
			CMML, MDS	NCT01404741	Recruiting
			AML	NCT02450877	Recruiting
		Vorinostat	AML, MDS	NCT01617226	Recruiting
		Panobinostat	AML, CMML, MDS	NCT00946647	Recruiting
		VPA, Lenalidomide	MDS	NCT01342692	Recruiting
		VPA	AML, MDS	NCT02124174	Recruiting
			AML, MDS	NCT01995578	Recruiting
			AML, MDS	NCT01462578	Recruiting
			MDS	NCT02281084	Recruiting
		Vorinostat	AML, MDS	NCT00948064	Ongoing
		Entinostat	AML, CMML, MDS,	NCT00313586	Ongoing
			MDS	NCT01599325	Ongoing
		Pracinostat	MDS	NCT01873703	Ongoing
			MDS	NCT00721214	Ongoing
		VPA, ATRA	AML, MDS	NCT00326170	Completed
		VPA, Cytarabine	AML, DMS	NCT00382590	Completed
			MDS	NCT00897130	Completed
			AML	NCT00739388	Completed
			AML	NCT00387647	Completed
			MDS	NCT00384956	Completed
		VPA, ATRA	MDS, AML	NCT00339196	Completed
		Sodium phenylbutyrate	AML, MDS, MM, NHL	NCT00006019	Completed
		VPA, ATRA	MDS	NCT00439673	Completed
			MDS	NCT00102687	Completed
			AML, MDS	NCT00915785	Completed
			CMML	NCT01235117	Completed
			MDS	NCT00446303	Terminated
			CLL	NCT00413478	Terminated
		Mocetinostat	AML, MDS	NCT00666497	Terminated
		Mocetinostat	HL, NHL	NCT00543582	Terminated
	II/III	Lenalidomide, Vorinostat	CMML, MDS	NCT01522976	Ongoing
	III		AML, MDS	NCT00887068	Recruiting
		CCR	AML	NCT01074047	Ongoing
			MDS	NCT01186939	Completed
			MDS	NCT00071799	Completed
			AML, MDS	NCT00422890	Completed
	IV		MDS	NCT01201811	Completed
Decitabine	I	OSU-HDAC42	AML	NCT01798901	Ongoing
		Vorinostat	AML, CMML, MDS	NCT00357708	Completed
		Vorinostat	AML, ALL, CLL, NHL	NCT00275080	Completed
		VPA	NHL	NCT00109824	Completed
		VPA	AML, CLL, SLL	NCT00079378	Completed
			AML, ALL	NCT00042796	Terminated
		Romidepsin	MDS	NCT00114257	Completed
		Cytarabine, Vorinostat	AML	NCT01130506	Completed
			MDS	NCT00941109	Completed
			MDS	NCT00796003	Completed
			ALL	NCT00349596	Completed
			AML, MDS	NCT00049582	Terminated
	I/II	Panobinostat	AML, MDS	NCT00691938	Ongoing
			MDS	NCT01165996	Completed
			MDS,	NCT00075010	Completed
	II		AML, MDS	NCT01687400	Recruiting
		VPA, ATRA	AML	NCT00867672	Recruiting
		VPA	AML, MDS	NCT00414310	Completed
			CMML, MDS	NCT00067808	Completed
			MDS	NCT00003361	Completed
			AML	NCT00866073	Completed
			MDS	NCT00619099	Completed
			CML	NCT00042003	Completed
			CML	NCT00042016	Completed
			CML	NCT00041990	Completed
			MDS	NCT00744757	Completed
			CMML, MDS	NCT00113321	Terminated
			MDS	NCT01333449	Terminated
	III		MDS	NCT01751867	Completed
			MDS	NCT00043381	Completed
Azacitidine versus Decitabine	II		MDS	NCT02269280	Recruiting
	II		MDS	NCT01720225	Recruiting
	III		MDS	NCT01409070	Completed
	IV		MDS	NCT01011283	Terminated
SGI-110	I		AML	NCT02293993	Recruiting
	I/II		AML, CMML, MDS	NCT01261312	Ongoing
	II	Idarubicin, Cladribine	AML	NCT02096055	Recruiting
			MDS	NCT02131597	Recruiting
			MDS	NCT02197676	Recruiting
	III		AML	NCT02348489	Recruiting

^aAHM, advanced hematologic cancers; AML, acute myeloid leukemia; ATRA, all-trans retinoic acid; CCR, Conventional Care Regimen; CLL, chronic lymphocytic leukemia; CML, chronic myeloid leukemia; CMML, chronic myelomonocytic leukemia; HL, Hodgkin's lymphoma; JMML, juvenile myelomonocytic leukemia; MDS, myelodysplastic sindrome; MM, multiple myeloma; NHL, non-Hodgkin lymphoma; SLL, small lymphocytic lymphoma; VA, valproic acid.

^bIdentifier of the trial as retrieved April, 2016, from: http://clinicaltrials.gov.